docetaxel/cisplatin

Phase 3Small molecule

docetaxel/cisplatin is one of 61 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

docetaxel/cisplatin

UUniversity of Vermont

Phase 3

1 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Imjudo

AstraZeneca

Preclinical

5 7

Vizimpro

Pfizer

Preclinical

4 8

Remeron

OOrganon and Co

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Nasopharyngeal Carcinoma

NCT03919552

Clinical

Trials by Indication[1]

Chemoradiation1 trial

Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC

Unknown status·PPeking University People's Hospital·Phase 2·NCT01771289·50 enrolled

Head and Neck Cancer1 trial

Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer

Unknown status·UUniversity of Vermont·Phase 1/2·NCT00982436·37 enrolled

Non-Small Cell Lung Cancer1 trial

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

Completed·—·Phase 2·NCT01204307·101 enrolled

Nasopharyngeal Carcinoma1 trial

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Recruiting·NNanfang Hospital, Southern Medical University·Phase 3·NCT03919552·482 enrolled

Adjuvant Chemotherapy1 trial

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)

Completed·SSpanish Lung Cancer Group·Phase 3·NCT00478699·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for docetaxel/cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — docetaxel/cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for docetaxel/cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Vermont company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Vermont

docetaxel/cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Chemoradiation1 trial

Head and Neck Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Nasopharyngeal Carcinoma1 trial

Adjuvant Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News